243 related articles for article (PubMed ID: 25050775)
41. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics.
Marrache S; Dhar S
Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16288-93. PubMed ID: 22991470
[TBL] [Abstract][Full Text] [Related]
42. Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration.
Wang G; Kucharski C; Lin X; Uludağ H
J Drug Target; 2010 Sep; 18(8):611-26. PubMed ID: 20158316
[TBL] [Abstract][Full Text] [Related]
43. Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO-PPO-PEO nanoparticles using OFAT experiments.
Simonoska Crcarevska M; Geskovski N; Calis S; Dimchevska S; Kuzmanovska S; Petruševski G; Kajdžanoska M; Ugarkovic S; Goracinova K
Eur J Pharm Sci; 2013 Apr; 49(1):65-80. PubMed ID: 23439240
[TBL] [Abstract][Full Text] [Related]
44. Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment.
Rawat P; Ahmad I; Thomas SC; Pandey S; Vohora D; Gupta S; Ahmad FJ; Talegaonkar S
Int J Pharm; 2016 Jun; 506(1-2):253-61. PubMed ID: 27113864
[TBL] [Abstract][Full Text] [Related]
45. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation.
Yang A; Yang L; Liu W; Li Z; Xu H; Yang X
Int J Pharm; 2007 Feb; 331(1):123-32. PubMed ID: 17097246
[TBL] [Abstract][Full Text] [Related]
46. Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.
Partikel K; Korte R; Stein NC; Mulac D; Herrmann FC; Humpf HU; Langer K
Eur J Pharm Biopharm; 2019 Aug; 141():70-80. PubMed ID: 31082511
[TBL] [Abstract][Full Text] [Related]
47. Andrographolide-loaded PLGA-PEG-PLGA micelles to improve its bioavailability and anticancer efficacy.
Zhang J; Li Y; Gao W; Repka MA; Wang Y; Chen M
Expert Opin Drug Deliv; 2014 Sep; 11(9):1367-80. PubMed ID: 24935153
[TBL] [Abstract][Full Text] [Related]
48. Polysaccharide-modified nanoparticles with intelligent CD44 receptor targeting ability for gene delivery.
Lin WJ; Lee WC
Int J Nanomedicine; 2018; 13():3989-4002. PubMed ID: 30022822
[TBL] [Abstract][Full Text] [Related]
49. SP94 Peptide-Functionalized PEG-PLGA Nanoparticle Loading with Cryptotanshinone for Targeting Therapy of Hepatocellular Carcinoma.
Nie X; Liu Y; Li M; Yu X; Yuan W; Huang S; Ren D; Wang Y; Wang Y
AAPS PharmSciTech; 2020 Apr; 21(4):124. PubMed ID: 32342227
[TBL] [Abstract][Full Text] [Related]
50. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
51. Preparation and Characterization of PLGA-PEG-PLGA Nanoparticles Containing Salidroside and Tamoxifen for Breast Cancer Therapy.
Yu X; Sun L; Tan L; Wang M; Ren X; Pi J; Jiang M; Li N
AAPS PharmSciTech; 2020 Jan; 21(3):85. PubMed ID: 31997020
[TBL] [Abstract][Full Text] [Related]
52. Iron hydroxide nanoparticles coated with poly(ethylene glycol)-poly(aspartic acid) block copolymer as novel magnetic resonance contrast agents for in vivo cancer imaging.
Kumagai M; Imai Y; Nakamura T; Yamasaki Y; Sekino M; Ueno S; Hanaoka K; Kikuchi K; Nagano T; Kaneko E; Shimokado K; Kataoka K
Colloids Surf B Biointerfaces; 2007 Apr; 56(1-2):174-81. PubMed ID: 17324561
[TBL] [Abstract][Full Text] [Related]
53. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery.
Lu W; Zhang Y; Tan YZ; Hu KL; Jiang XG; Fu SK
J Control Release; 2005 Oct; 107(3):428-48. PubMed ID: 16176844
[TBL] [Abstract][Full Text] [Related]
54. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo.
Xu Q; Ensign LM; Boylan NJ; Schön A; Gong X; Yang JC; Lamb NW; Cai S; Yu T; Freire E; Hanes J
ACS Nano; 2015 Sep; 9(9):9217-27. PubMed ID: 26301576
[TBL] [Abstract][Full Text] [Related]
55. Surface Mechanical and Rheological Behaviors of Biocompatible Poly((D,L-lactic acid-ran-glycolic acid)-block-ethylene glycol) (PLGA-PEG) and Poly((D,L-lactic acid-ran-glycolic acid-ran-ε-caprolactone)-block-ethylene glycol) (PLGACL-PEG) Block Copolymers at the Air-Water Interface.
Kim HC; Lee H; Khetan J; Won YY
Langmuir; 2015 Dec; 31(51):13821-33. PubMed ID: 26633595
[TBL] [Abstract][Full Text] [Related]
56. [Synthesis of a bio-active bone-matrix material and study of the cellular biocompatibility].
Hao J; Zheng Q; Guo X; Quan D; Luo B
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Jun; 22(3):433-7. PubMed ID: 16013230
[TBL] [Abstract][Full Text] [Related]
57. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate.
Gao Y; Sun Y; Ren F; Gao S
Drug Dev Ind Pharm; 2010 Oct; 36(10):1131-8. PubMed ID: 20334543
[TBL] [Abstract][Full Text] [Related]
58. Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.
Li Z; Huang H; Huang L; Du L; Sun Y; Duan Y
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28406431
[TBL] [Abstract][Full Text] [Related]
59. Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG.
Haggag Y; Abdel-Wahab Y; Ojo O; Osman M; El-Gizawy S; El-Tanani M; Faheem A; McCarron P
Int J Pharm; 2016 Feb; 499(1-2):236-246. PubMed ID: 26746800
[TBL] [Abstract][Full Text] [Related]
60. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
